Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Consensus Rating of “Buy” from Analysts

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) have been assigned a consensus rating of “Buy” from the eleven analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and three have issued a strong buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $44.50.

MAZE has been the topic of several recent analyst reports. BTIG Research upped their price target on Maze Therapeutics from $37.00 to $46.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Guggenheim reaffirmed a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research report on Friday, December 19th. Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Raymond James Financial initiated coverage on Maze Therapeutics in a research report on Thursday, November 13th. They issued an “outperform” rating and a $48.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd.

Maze Therapeutics Stock Performance

MAZE stock opened at $46.97 on Wednesday. Maze Therapeutics has a one year low of $6.71 and a one year high of $49.25. The firm has a market cap of $2.26 billion and a PE ratio of -2.25. The firm’s 50 day moving average price is $42.67 and its 200-day moving average price is $31.73.

Insider Activity at Maze Therapeutics

In other Maze Therapeutics news, SVP Amy Bachrodt sold 10,000 shares of Maze Therapeutics stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $40.58, for a total value of $405,800.00. Following the completion of the transaction, the senior vice president directly owned 12,965 shares of the company’s stock, valued at $526,119.70. The trade was a 43.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Atul Dandekar sold 72,400 shares of the stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the sale, the insider directly owned 10,503 shares in the company, valued at $426,001.68. This represents a 87.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 200,000 shares of company stock worth $8,254,792 in the last three months.

Institutional Trading of Maze Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Ensign Peak Advisors Inc purchased a new position in Maze Therapeutics in the second quarter valued at $227,000. Frazier Life Sciences Management L.P. boosted its position in shares of Maze Therapeutics by 10.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after acquiring an additional 438,274 shares in the last quarter. Washington University purchased a new position in shares of Maze Therapeutics in the 3rd quarter valued at about $5,463,000. Virtus Investment Advisers LLC acquired a new stake in shares of Maze Therapeutics during the 2nd quarter worth about $85,000. Finally, CW Advisors LLC acquired a new stake in shares of Maze Therapeutics during the 2nd quarter worth about $371,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.